Brian J Long

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. ncbi The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model
    Brian J Long
    Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Clin Cancer Res 8:2378-88. 2002
  2. ncbi Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens
    Angela Brodie
    Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland 21202 1559, USA
    Clin Cancer Res 9:455S-9S. 2003
  3. ncbi Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo
    Stacey A Taylor
    Schering Plough Research Institute, Biological Research Oncology, 2015 Galloping Hill Road, K15 2 2700, Kenilworth, NJ 07033, USA
    Gynecol Oncol 109:97-106. 2008
  4. ncbi Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole
    Danijela Jelovac
    Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Cancer Res 65:5380-9. 2005
  5. ncbi Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model
    Brian J Long
    Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Health Sciences Facility, Baltimore, MD 21201, USA
    J Natl Cancer Inst 96:456-65. 2004
  6. ncbi Effects of exemestane and tamoxifen in a postmenopausal breast cancer model
    Danijela Jelovac
    Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Clin Cancer Res 10:7375-81. 2004
  7. ncbi Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens
    Apinya Thiantanawat
    Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Health Science Facility, Room 580G, 685 West Baltimore Street, Baltimore, MD 21201, USA
    Cancer Res 63:8037-50. 2003
  8. ncbi Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model
    Venkatesh D Handratta
    Department of Pharmacology and Experimental Therapeutics, School of Medicine, University of Maryland, Baltimore, MD 21201-1559, USA
    J Steroid Biochem Mol Biol 92:155-65. 2004
  9. ncbi Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336)
    Gonjgie Liu
    Department of Biological Research Oncology, Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
    Anticancer Drugs 18:923-31. 2007
  10. ncbi The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity
    Andrea D Basso
    Department of Tumor Biology, Schering Plough Research Institute, Kenilwort, New Jersey 07033, USA
    J Biol Chem 280:31101-8. 2005

Collaborators

  • James N Ingle
  • Joseph Ragaz
  • Angela H Brodie
  • VINCENT C NJAR
  • Danijela Jelovac
  • Stacey A Taylor
  • W Robert Bishop
  • Paul Kirschmeier
  • Andrea D Basso
  • Ming Liu
  • Cindy H Marrinan
  • Gonjgie Liu
  • Gongjie Liu
  • Olga G Goloubeva
  • Luciana Macedo
  • Venkatesh D Handratta
  • Apinya Thiantanawat
  • Lissette Nale
  • Stuart Black
  • Gauri Sabnis
  • Asra Mirza
  • Venkatesh Handratta
  • Ivo P Nnane
  • Ritesh Kataria

Detail Information

Publications10

  1. ncbi The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model
    Brian J Long
    Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Clin Cancer Res 8:2378-88. 2002
    ....
  2. ncbi Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens
    Angela Brodie
    Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland 21202 1559, USA
    Clin Cancer Res 9:455S-9S. 2003
    ..These results demonstrate that this aromatase inhibitor is more effective and has a longer duration of response as a single agent than tamoxifen or in combination with tamoxifen...
  3. ncbi Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo
    Stacey A Taylor
    Schering Plough Research Institute, Biological Research Oncology, 2015 Galloping Hill Road, K15 2 2700, Kenilworth, NJ 07033, USA
    Gynecol Oncol 109:97-106. 2008
    ....
  4. ncbi Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole
    Danijela Jelovac
    Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Cancer Res 65:5380-9. 2005
    ..These results indicate that blocking both ER- and growth factor-mediated transcription resulted in the most effective inhibition of growth of ER-positive breast cancer cells...
  5. ncbi Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model
    Brian J Long
    Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Health Sciences Facility, Baltimore, MD 21201, USA
    J Natl Cancer Inst 96:456-65. 2004
    ..However, further studies are needed to determine the most effective second-line therapy for tumors that progress on letrozole...
  6. ncbi Effects of exemestane and tamoxifen in a postmenopausal breast cancer model
    Danijela Jelovac
    Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Clin Cancer Res 10:7375-81. 2004
    ..However, the nonsteroidal aromatase inhibitor letrozole as first-line therapy was overall the most effective treatment in controlling tumor growth...
  7. ncbi Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens
    Apinya Thiantanawat
    Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Health Science Facility, Room 580G, 685 West Baltimore Street, Baltimore, MD 21201, USA
    Cancer Res 63:8037-50. 2003
    ....
  8. ncbi Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model
    Venkatesh D Handratta
    Department of Pharmacology and Experimental Therapeutics, School of Medicine, University of Maryland, Baltimore, MD 21201-1559, USA
    J Steroid Biochem Mol Biol 92:155-65. 2004
    ..These results indicate that VN/85-1 or VN/87-1 may be useful in the treatment of hormone-dependent prostate cancer...
  9. ncbi Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336)
    Gonjgie Liu
    Department of Biological Research Oncology, Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
    Anticancer Drugs 18:923-31. 2007
    ..These studies indicate that lonafarnib enhances the efficacy of endocrine agents clinically used for treating hormone-dependent breast cancer...
  10. ncbi The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity
    Andrea D Basso
    Department of Tumor Biology, Schering Plough Research Institute, Kenilwort, New Jersey 07033, USA
    J Biol Chem 280:31101-8. 2005
    ..These studies demonstrated that Rheb is modified by farnesylation, is not a substrate for alternative prenylation, and plays a role in SCH66336 enhancement of the anti-tumor response to other chemotherapeutics...